# Talampanel for Amyotrophic Lateral Sclerosis (ALS)

> **NCT00696332** · PHASE2 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 559 (actual)

## Conditions studied

- ALS

## Interventions

- **DRUG:** Talampanel
- **DRUG:** Talampanel
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00696332
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2010-04
- **Final completion:** 2010-05
- **Target enrollment:** 559 (ACTUAL)
- **Last updated:** 2011-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00696332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00696332, "Talampanel for Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00696332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*